Can a copycat epilepsy drug match the original? a trial puts it to the test

NCT ID NCT07800533

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This Phase 1 trial checks whether a new coated tablet containing brivaracetam delivers the same amount of the drug into the bloodstream as the reference product Briviact. Researchers give a single dose of each version to 28 healthy adults under fasting conditions and compare key measures like peak concentration and total exposure. The goal is to see if the two formulations are bioequivalent, meaning they behave alike in the body. If they do, the test tablet could serve as a generic alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brivaracetam
What this could lead to
If the test tablet proves equivalent, it could become a lower-cost generic alternative to Briviact for people who need brivaracetam.
What could go wrong
This is a small early-stage study in healthy volunteers, not patients. Even if the tablets match, regulators must still approve the generic, and results may not predict effects in people with epilepsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Aug 2024

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) between 18.5 and 30.0 kg/m². Non-smokers or former smokers who stopped smoking at least 1 year prior to screening. Clinically healthy based on medical history, physical examination, vital signs, ECG, and clinical laboratory tests. Negative screening for HIV, hepatitis B, and hepatitis C. Female participants must not be pregnant or breastfeeding and must have a negative pregnancy test. No hair, wounds, or dermatological conditions at the intended patch application site (upper arm). Able to understand the study procedures and provide written informed consent Exclusion Criteria: * History or presence of clinically significant cardiovascular, hepatic, renal, gastrointestinal, neurological, psychiatric, metabolic, pulmonary, or dermatological diseases. * Known hypersensitivity to rivastigmine, carbamate derivatives, or any component of the study formulation. * Abnormal clinical laboratory results, vital signs, or ECG considered clinically significant by the investigator. * Positive test results for drugs of abuse, alcohol misuse, HIV, hepatitis B, or hepatitis C. * Use of prescription or non-prescription medications that could interfere with the study drug within a defined period prior to dosing, as determined by the investigator. * Participation in another clinical trial or exposure to an investigational drug within the previous 6 months. * Blood donation or significant blood loss within 3 months prior to the study. * Consumption of grapefruit-containing products, alcohol, or substances that could interfere with drug metabolism prior to dosing. * Use of medications known to significantly affect hepatic metabolism. * Positive or suspected infection with SARS-CoV-2 prior to study periods. * Any condition that, in the investigator's judgment, could interfere with study participation or the interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bioequivalence study in healthy subjects are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Unidade Integrada de Farmacologia e Gastroenterologia (UNIFAG)

    Bragança Paulista, São Paulo, 12916-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.